Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

被引：2

作者：

Sadeghi, S. ^{[1
]}

Quinn, D. I. ^{[1
]}

Dorff, T. ^{[2
]}

Pal, S. K. ^{[2
,3
]}

Groshen, S. ^{[3
]}

Tsao-Wei, D. ^{[3
]}

Lara, P. N. ^{[4
]}

Parikh, R. ^{[5
]}

Devitt, M. E. ^{[5
]}

Parikh, M. ^{[4
]}

Jackovich, A. ^{[7
]}

Vogelzang, N. J. ^{[8
]}

Burgess, E. F. ^{[9
]}

Dreicer, R. ^{[6
]}

Siddiqi, I. ^{[10
]}

Gill, I. ^{[11
]}

Gill, P. ^{[1
]}

机构：

[1] USC Norris Comprehens Canc Ctr, Med, Los Angeles, CA USA

[2] City Hope Comprehens Canc Ctr, Oncol, Duarte, CA USA

[3] USC Univ Southern Calif, Keck Sch Med, Oncol, Los Angeles, CA USA

[4] Univ Calif Davis, Ctr Canc, Oncol, Sacramento, CA 95817 USA

[5] Univ Kansas, Oncol, Westwood, KS USA

[6] Univ Virginia, Ctr Canc, Med, Charlottesville, VA USA

[7] Rutgers State Univ, Med, New Brunswick, NJ USA

[8] Comprehens Canc Crts NV, Comprehens Canc Ctr Nevada, US Oncol Res, Las Vegas, NV USA

[9] Levine Canc Inst, Dept Med Oncol, Charlotte, NC USA

[10] USC Norris Comprehens Canc Ctr, Pathol, Los Angeles, CA USA

[11] USC Norris Comprehens Canc Ctr, Urol, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

651O

引用

页码：S678 / S678

页数：1